Dioscin improves postmenopausal osteoporosis through inducing bone formation and inhibiting apoptosis in ovariectomized rats

Wu, Shan; Zhao, Fan; Zhao, Jing; Li, Hui; Chen, Junyu; Xia, Yang; Wang, Junwei; Zhao, Benzheng; Zhao, Shuhua; Li, Na

doi:10.5582/bst.2019.01186

Cited by 20 publications

(13 citation statements)

References 41 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 15 The best-known source of various steroidal saponins, including spirostane and furostane types, is fenugreek ( Trigonella foenum graecum ) seeds. 16 In recent years, diosgenin has attracted increasing attention due to its efficacy in treating various metabolic diseases, including diabetes, 17 CVDs, 18 neurological disease, 19 osteoporosis, 20 and hyperlipidemia, 21 in addition to anti-cancer effects, which are mediated via multiple targets and regulate various signals. 22 , 23 Numerous animal experiments and clinical trials have shown that diosgenin can reduce blood lipids by lowering plasma low-density lipoprotein (LDL) and increasing high-density lipoprotein (HDL).…”

Section: Introductionmentioning

confidence: 99%

The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A Review

Sun

Yang

et al. 2021

DMSO

View full text Add to dashboard Cite

Hyperlipidemia is a disorder of lipid metabolism, which is a major cause of coronary heart disease. Although there has been considerable progress in hyperlipidemia treatment, morbidity and risk associated with the condition continue to rise. The first-line treatment for hyperlipidemia, statins, has multiple side effects; therefore, development of safe and effective drugs from natural products to prevent and treat hyperlipidemia is necessary. Diosgenin is primarily derived from fenugreek ( Trigonella foenum graecum ) seeds, and is also abundant in medicinal herbs such as Dioscorea rhizome, Dioscorea septemloba , and Rhizoma polygonati , is a well-known steroidal sapogenin and the active ingredient in many drugs to treat cardiovascular conditions. There is abundant evidence that diosgenin has potential for application in correcting lipid metabolism disorders. In this review, we evaluated the latest evidence related to diosgenin and hyperlipidemia from clinical and animal studies. Additionally, we elaborate the pharmacological mechanism underlying the activity of diosgenin in treating hyperlipidemia in detail, including its role in inhibition of intestinal absorption of lipids, regulation of cholesterol transport, promotion of cholesterol conversion into bile acid and its excretion, inhibition of endogenous lipid biosynthesis, antioxidation and lipoprotein lipase activity, and regulation of transcription factors related to lipid metabolism. This review provides a deep exploration of the pharmacological mechanisms involved in diosgenin-hyperlipidemia interactions and suggests potential routes for the development of novel drug therapies for hyperlipidemia.

show abstract

Section: Introductionmentioning

confidence: 99%

The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A Review

Sun

Yang

et al. 2021

DMSO

View full text Add to dashboard Cite

show abstract

“…MTT assay was performed as described previously 41 . Simply, Siha cells were seeded into 96-well plates at 2 × 10 3 cells/well.…”

Section: Methodsmentioning

confidence: 99%

“…Hematoxylin and eosin (H&E) stained was performed as described previously 41 . The images were subsequently acquired using a light microscope with 200× magnification.…”

Section: Methodsmentioning

confidence: 99%

Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy

Chen

Zhao

Tan

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

Human papillomavirus (HPV) infection is the major etiological factor for cervical cancer. HPV prophylactic vaccines based on L1 virus-like particles have been considered as an effective prevention method. However, existing recombination vaccines are too expensive for developing countries. DNA vaccines might be a lower-cost and effective alternative. In this study, a plasmid (pcDNA3.1-HPV16-L1) and a co-expressing plasmid (pcDNA3.1-HPV16-L1-siE6) carried by attenuated Salmonella were constructed and their prevention and treatment effect on cervical cancer were observed, respectively. The results showed that pcDNA3.1-HPV16-L1 carried by attenuated Salmonella could induce the production of HPV16-L1 antibodies, IL-2 and INF-γ in mice serum, which presented its prevention effect on HPV. Subsequently, E6 and E7 gene silencing by pCG-siE6 inhibited the growth of cervical cancer both in vitro and in vivo. Furthermore, L1 up-regulation and E6/E7 down-regulation caused by co-expressing plasmid (pcDNA3.1-HPV16-L1-siE6) contributed to a significant anti-tumor effect on the mice. This study suggests that pcDNA3.1-HPV16-L1-siE6 carried by attenuated Salmonella has a synergistic effect of immune regulation and RNA interference in cervical cancer treatment.

show abstract

“…Bone-specific treatment is needed for treatment of osteoporosis, and individual formulations should be used in light of the benefit-risk balance (59). Some of the main ingredients in medicinal plants, such as dioscin, have proven to be effective in animal models, but more clinical trials need to be conducted (60).…”

Section: Osteoporosis Preventionmentioning

confidence: 99%

Update on hormone therapy for the management of postmenopausal women

Pan

Zhou

et al. 2022

BST

View full text Add to dashboard Cite

Hormone therapy (HT) has been used in postmenopausal women for decades in clinical practice. With further analysis and newer studies, the benefits and risks of HT have been repeatedly verified and discussed. HT is recommended for the treatment of vasomotor symptoms (VMS), genitourinary syndrome of menopause (GSM) and the prevention of osteoporosis. However, the precise association between HT and the risks of cardiovascular diseases, venous thromboembolism, neurodegenerative diseases, breast cancer, and endometrial cancer remains controversial. Therefore, determining how to take advantage of and control the risks of HT by adjusting the initiation time, regimen, and duration is crucial. Recent studies have indicated that HT is not related to the risk of all-cause, cardiovascular, or breast cancer mortality although it might increase the incidence of some chronic diseases. For symptomatic postmenopausal women under the age of 60 without contraindications, early initiation of HT is safe and probably has a mortality benefit over the long term. Initiating HT close to menopause at the lowest effective dose is more likely to have maximal benefits and the lowest risks. Transdermal and vaginal HT may have a lower risk, but recent evidence suggests additional clinical benefits of oral HT formulations in relieving VMS and preventing osteoporosis. The pooled cohort risk equation for atherosclerotic cardiovascular disease (ASCVD) and the free app named Menopro can be used to perform individual risk assessments. In addition, Chinese herbal medicines have benefits in alleviating hot flashes, depression, and menopausal symptoms, although further data are needed to strongly support their efficacy. Acupuncture and electroacupuncture have definite efficacy in the treatment of postmenopausal symptoms with few adverse effects, so they are a reasonable option as an alternative therapy for high-risk women. This review discusses the history of, guidelines on, and strategies for HT in order to make suggestions based on the most up-to-date evidence for the management of postmenopausal women.

show abstract

Dioscin improves postmenopausal osteoporosis through inducing bone formation and inhibiting apoptosis in ovariectomized rats

Cited by 20 publications

References 41 publications

The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A Review

The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A Review

Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy

Update on hormone therapy for the management of postmenopausal women

Contact Info

Product

Resources

About